## Brigitte Michelsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7230321/publications.pdf

Version: 2024-02-01

687363 677142 23 641 13 22 citations g-index h-index papers 23 23 23 917 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Annals of the Rheumatic Diseases, 2017, 76, 1906-1910.	0.9	162
2	A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis. PLoS ONE, 2015, 10, e0123582.	2.5	94
3	Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Annals of the Rheumatic Diseases, 2017, 76, 708-711.	0.9	45
4	Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Annals of the Rheumatic Diseases, 2016, 75, 2108-2113.	0.9	40
5	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280.	3.8	33
6	Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. Arthritis Research and Therapy, 2020, 22, 198.	3.5	31
7	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. Annals of the Rheumatic Diseases, 2018, 77, 1736-1741.	0.9	30
8	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.9	28
9	Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. Annals of the Rheumatic Diseases, 2018, 77, 1290-1294.	0.9	21
10	Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open, 2020, 6, e001223.	3.8	21
11	Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open, 2018, 4, e000631.	3.8	20
12	Realâ€World Six―and Twelveâ€Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	3.4	20
13	Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. Journal of Rheumatology, 2017, 44, 431-436.	2.0	18
14	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Research and Therapy, 2018, 20, 160.	3.5	16
15	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology, 2021, 60, 3635-3645.	1.9	14
16	Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study. Seminars in Arthritis and Rheumatism, 2020, 50, 12-16.	3.4	13
17	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14Â868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
18	European bio-naÃ-ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	1.9	7

#	Article	IF	CITATIONS
19	Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. RMD Open, 2020, 6, e001372.	3.8	6
20	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	1.9	6
21	Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. PLoS ONE, 2022, 17, e0266816.	2.5	6
22	Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. Rheumatology and Therapy, 2022, 9, 1171-1179.	2.3	2
23	FRIO439â€PERCEIVED INFLUENCE OF HEALTH STATUS ON SEXUAL ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS IS ASSOCIATED WITH MUSCULOSKELETAL MANIFESTATIONS BUT NOT WITH PSORIASIS SKIN MANIFESTATIONS. , 2019, , .		1